Patients For Affordable Drugs, Public Citizen, Legal Expert & Patient React to SCOTUS Denying Pharma Lawsuits Challenging Medicare Drug Price Negotiation
WASHINGTON, D.C. — This morning, the Supreme Court denied petitions from six major drugmakers — AstraZeneca, Bristol Myers Squibb, Janssen, Novartis, Novo Nordisk, and Boehringer Ingelheim — leaving in place lower court rulings that rejected their challenges to the Medicare Drug Price Negotiation Program.
At 10:30 am ET today, Patients For Affordable Drugs (P4AD) and Public Citizen will host a virtual press briefing with a legal expert and a patient advocate to break down what this decision means for patients, whether this marks the end of the line for these cases, and what it signals for the future of the pharmaceutical industry’s legal strategy. The decision follows a series of losses for drugmakers in district and appellate courts across the country.
EVENT DETAILS:
- WHEN: Monday, May 18th at 10:30 am ET
- WHERE: Virtual Press Briefing (Zoom link will be shared upon RSVP)
- WHO:
- Merith Basey, CEO, Patients For Affordable Drugs
- Peter Maybarduk, Access to Medicines Director, Public Citizen
- Michael Lieberman, Fairmark Partners LLP
- Judy Aiken, Patient Advocate from Maine
There will be time for Q&A after the speakers conclude their remarks. To RSVP, please fill out this form.